Rational approach to aids drug design through structural biology

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 595-614

  Wlodawer, Alexander ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 77003; ABACAVIR; AG 1002; AG 1004; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; INDINAVIR; L 682 679; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MOZENAVIR; NELFINAVIR; PEPSTATIN; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RO 31 8558; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG DESIGN; DRUG STRUCTURE; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TREATMENT OUTCOME; VIRUS RESISTANCE; X RAY CRYSTALLOGRAPHY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036176766     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.052901.131947     Document Type: Review

References (106)

1. Design of enzyme inhibitors using iterative protein crystallographic analysis
2. Recent advances in structure-based rational drug design
3. Recent developments in structure-based drug design
4. Combinatorial synthesis of small molecules
5. Complete nucleotide sequence of the AIDS virus, HTLV-III
6. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
7. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA
8. Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases
9. The catalytic domain of human immunodeficiency virus integrase: Ordered active site in the F185H mutant
10. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases
11. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding
12. HIV-1 integrase as a target for antiviral drugs
13. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor
14. Active human immunodeficiency virus protease is required for viral infectivity
15. Structure-based inhibitors of HIV-1 protease
16. Clinically effective HIV-1 protease inhibitors
17. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
18. HIV protease: Enzyme function and drug resistance
19. Structural and biochemical studies of retroviral proteases
20. Targeting the HIV-protease in AIDS therapy: A current clinical perspective
21. Drugs targeted at HIV - Successes and resistance
22. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance
23. Retroviral protease-like sequence in the yeast transposon Ty1
24. The structure and function of the aspartic proteinases
25. Murine leukemia virus maturation: Protease region required for conversion from immature to mature form and for virus infectivity
26. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A
27. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
28. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease
29. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes
30. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures
31. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors
32. Three-dimensional structure of a simian immunodeficiency virus protease/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 protease inhibitors
33. Structure of the protease from simian immunodeficiency virus: Complex with an irreversible nonpeptide inhibitor
34. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
35. Database of three-dimensional structures of HIV proteinases
36. A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: Structural and modeling studies
37. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease
38. Secondary structure and signal assignments of human-immunodeficiency-virus-1 protease complexed to a novel, structure-based inhibitor
39. Solution conformations of KNI-272, a tripeptide HIV protease inhibitor designed on the basis of substrate transition state: Determined by NMR spectroscopy and simulated annealing calculations
40. Design, synthesis, and conformational analysis of a novel macrocyclic HIV-protease inhibitor
41. Ionization states of the catalytic residues in HIV-1 protease
42. Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations
43. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution
44. On the size of the active site in proteases. I. Papain
45. Molecular mechanics analysis of inhibitor binding to HIV-1 protease
46. Energy calculations and analysis of HIV-1 protease-inhibitor crystal structure
47. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site
48. Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease
49. Application of free energy simulations to the binding of a transition-state-analogue inhibitor to HIV protease
50. Solution structure of HIV-1 protease-allophenylnorstatine derivative inhibitor complex obtained from molecular dynamics simulation
51. Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease
52. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
53. A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design
54. Monte Carlo docking of oligopeptides to proteins
55. Group-build: A fragment-based method for de novo drug design
56. Empirical free energy as a target function in docking and design: Application to HIV-1 protease inhibitors
57. Ongoing trials in HIV protease inhibitors
58. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors
59. Rational design of peptide-based HIV proteinase inhibitors
60. The three-dimensional x-ray crystal structure of HIV-1 protease complexed with a hydroxyethylene inhibitor
61. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere
62. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
63. Design and structure of symmetry-based inhibitors of HIV-1 protease
64. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
65. A symmetric inhibitor binds HIV-1 protease asymmetrically
66. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
67. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
68. Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes
69. Renin inhibitors
70. Design and synthesis of HIV pro inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679
71. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor
72. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
73. Crystal structures of HIV-1 protease-inhibitor complexes
74. Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease
75. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease
76. De novo design of enzyme inhibitors by Monte Carlo ligand generation
77. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease
78. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
79. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
80. Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor
81. Amprenavir: A review of its clinical potential in patients with HIV infection
82. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
83. ABT-378 Abbott Laboratories
84. Lopinavir
85. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
86. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor
87. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors
88. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor
89. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV
90. Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450
91. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro4-hydroxy-2-pyrone sulfonamide class
92. Structure-based discovery of Tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor
93. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors
94. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents
95. Comparison of three different crystal forms shows HIV-1 reverse transcriptase displays an internal swivel motion
96. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
97. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter
98. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial
99. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative
100. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
101. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor
102. The role of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
103. Mutations in retroviral genes associated with drug resistance
104. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors